Solventum (SOLV) Competitors

$74.43 -0.67 (-0.89%)

Closing price 05/13/2026 03:59 PM Eastern

Extended Trading

$74.43 +0.00 (+0.00%)

As of 04:00 AM Eastern

SOLV vs. GEHC, PHG, ZBH, SNN, and PEN

Should you buy Solventum stock or one of its competitors? MarketBeat compares Solventum with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Solventum include GE HealthCare Technologies (GEHC), Koninklijke Philips (PHG), Zimmer Biomet (ZBH), Smith & Nephew SNATS (SNN), and Penumbra (PEN). These companies are all part of the "medical equipment" industry.

How does Solventum compare to GE HealthCare Technologies?

Solventum (NYSE:SOLV) and GE HealthCare Technologies (NASDAQ:GEHC) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

In the previous week, GE HealthCare Technologies had 4 more articles in the media than Solventum. MarketBeat recorded 10 mentions for GE HealthCare Technologies and 6 mentions for Solventum. GE HealthCare Technologies' average media sentiment score of 0.91 beat Solventum's score of 0.30 indicating that GE HealthCare Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solventum	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
GE HealthCare Technologies	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Solventum presently has a consensus price target of $85.91, suggesting a potential upside of 15.42%. GE HealthCare Technologies has a consensus price target of $80.67, suggesting a potential upside of 30.34%. Given GE HealthCare Technologies' higher probable upside, analysts clearly believe GE HealthCare Technologies is more favorable than Solventum.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solventum	1 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.46
GE HealthCare Technologies	1 Sell rating(s)	8 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.41

GE HealthCare Technologies has higher revenue and earnings than Solventum. Solventum is trading at a lower price-to-earnings ratio than GE HealthCare Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solventum	$8.33B	1.55	$1.56B	$8.16	9.12
GE HealthCare Technologies	$20.63B	1.37	$2.08B	$4.18	14.81

Solventum has a net margin of 17.33% compared to GE HealthCare Technologies' net margin of 9.10%. Solventum's return on equity of 23.51% beat GE HealthCare Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solventum	17.33%	23.51%	7.63%
GE HealthCare Technologies	9.10%	20.46%	5.73%

82.1% of GE HealthCare Technologies shares are held by institutional investors. 0.2% of Solventum shares are held by company insiders. Comparatively, 0.4% of GE HealthCare Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Solventum has a beta of 0.59, meaning that its share price is 41% less volatile than the broader market. Comparatively, GE HealthCare Technologies has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market.

Summary

GE HealthCare Technologies beats Solventum on 10 of the 16 factors compared between the two stocks.

How does Solventum compare to Koninklijke Philips?

Koninklijke Philips (NYSE:PHG) and Solventum (NYSE:SOLV) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, media sentiment, earnings, analyst recommendations, valuation and profitability.

Solventum has lower revenue, but higher earnings than Koninklijke Philips. Solventum is trading at a lower price-to-earnings ratio than Koninklijke Philips, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Koninklijke Philips	$20.17B	1.22	$1.01B	$1.17	21.92
Solventum	$8.33B	1.55	$1.56B	$8.16	9.12

In the previous week, Solventum had 1 more articles in the media than Koninklijke Philips. MarketBeat recorded 6 mentions for Solventum and 5 mentions for Koninklijke Philips. Koninklijke Philips' average media sentiment score of 0.65 beat Solventum's score of 0.30 indicating that Koninklijke Philips is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Koninklijke Philips	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Solventum	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

13.7% of Koninklijke Philips shares are held by institutional investors. 0.2% of Solventum shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Solventum has a consensus price target of $85.91, indicating a potential upside of 15.42%. Given Solventum's stronger consensus rating and higher probable upside, analysts plainly believe Solventum is more favorable than Koninklijke Philips.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Koninklijke Philips	0 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Solventum	1 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.46

Koninklijke Philips has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market. Comparatively, Solventum has a beta of 0.59, meaning that its share price is 41% less volatile than the broader market.

Solventum has a net margin of 17.33% compared to Koninklijke Philips' net margin of 5.49%. Solventum's return on equity of 23.51% beat Koninklijke Philips' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Koninklijke Philips	5.49%	13.51%	5.48%
Solventum	17.33%	23.51%	7.63%

Summary

Solventum beats Koninklijke Philips on 11 of the 16 factors compared between the two stocks.

How does Solventum compare to Zimmer Biomet?

Zimmer Biomet (NYSE:ZBH) and Solventum (NYSE:SOLV) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, media sentiment, earnings, analyst recommendations, valuation and profitability.

Solventum has higher revenue and earnings than Zimmer Biomet. Solventum is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zimmer Biomet	$8.23B	1.94	$705.20M	$3.85	21.47
Solventum	$8.33B	1.55	$1.56B	$8.16	9.12

In the previous week, Zimmer Biomet had 4 more articles in the media than Solventum. MarketBeat recorded 10 mentions for Zimmer Biomet and 6 mentions for Solventum. Zimmer Biomet's average media sentiment score of 0.85 beat Solventum's score of 0.30 indicating that Zimmer Biomet is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zimmer Biomet	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Solventum	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

88.9% of Zimmer Biomet shares are held by institutional investors. 1.3% of Zimmer Biomet shares are held by insiders. Comparatively, 0.2% of Solventum shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Zimmer Biomet currently has a consensus price target of $102.80, indicating a potential upside of 24.35%. Solventum has a consensus price target of $85.91, indicating a potential upside of 15.42%. Given Zimmer Biomet's higher probable upside, research analysts plainly believe Zimmer Biomet is more favorable than Solventum.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zimmer Biomet	3 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.26
Solventum	1 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.46

Zimmer Biomet has a beta of 0.48, meaning that its share price is 52% less volatile than the broader market. Comparatively, Solventum has a beta of 0.59, meaning that its share price is 41% less volatile than the broader market.

Solventum has a net margin of 17.33% compared to Zimmer Biomet's net margin of 9.05%. Solventum's return on equity of 23.51% beat Zimmer Biomet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zimmer Biomet	9.05%	13.24%	7.28%
Solventum	17.33%	23.51%	7.63%

Summary

Zimmer Biomet and Solventum tied by winning 8 of the 16 factors compared between the two stocks.

How does Solventum compare to Smith & Nephew SNATS?

Smith & Nephew SNATS (NYSE:SNN) and Solventum (NYSE:SOLV) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability and risk.

In the previous week, Solventum had 4 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 6 mentions for Solventum and 2 mentions for Smith & Nephew SNATS. Solventum's average media sentiment score of 0.30 beat Smith & Nephew SNATS's score of 0.23 indicating that Solventum is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Smith & Nephew SNATS	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Solventum	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Smith & Nephew SNATS presently has a consensus price target of $30.93, indicating a potential upside of 3.65%. Solventum has a consensus price target of $85.91, indicating a potential upside of 15.42%. Given Solventum's stronger consensus rating and higher possible upside, analysts clearly believe Solventum is more favorable than Smith & Nephew SNATS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Smith & Nephew SNATS	0 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.40
Solventum	1 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.46

Solventum has a net margin of 17.33% compared to Smith & Nephew SNATS's net margin of 0.00%. Solventum's return on equity of 23.51% beat Smith & Nephew SNATS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Smith & Nephew SNATS	N/A	N/A	N/A
Solventum	17.33%	23.51%	7.63%

Smith & Nephew SNATS has a beta of 0.57, meaning that its stock price is 43% less volatile than the broader market. Comparatively, Solventum has a beta of 0.59, meaning that its stock price is 41% less volatile than the broader market.

Solventum has higher revenue and earnings than Smith & Nephew SNATS.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Smith & Nephew SNATS	$6.16B	2.07	$625M	N/A	N/A
Solventum	$8.33B	1.55	$1.56B	$8.16	9.12

25.6% of Smith & Nephew SNATS shares are held by institutional investors. 1.0% of Smith & Nephew SNATS shares are held by insiders. Comparatively, 0.2% of Solventum shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Solventum beats Smith & Nephew SNATS on 11 of the 15 factors compared between the two stocks.

How does Solventum compare to Penumbra?

Solventum (NYSE:SOLV) and Penumbra (NYSE:PEN) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and risk.

In the previous week, Penumbra had 2 more articles in the media than Solventum. MarketBeat recorded 8 mentions for Penumbra and 6 mentions for Solventum. Solventum's average media sentiment score of 0.30 beat Penumbra's score of 0.03 indicating that Solventum is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solventum	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Penumbra	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

88.9% of Penumbra shares are held by institutional investors. 0.2% of Solventum shares are held by company insiders. Comparatively, 2.9% of Penumbra shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Solventum has a beta of 0.59, meaning that its share price is 41% less volatile than the broader market. Comparatively, Penumbra has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market.

Solventum currently has a consensus price target of $85.91, suggesting a potential upside of 15.42%. Penumbra has a consensus price target of $361.33, suggesting a potential upside of 12.05%. Given Solventum's stronger consensus rating and higher probable upside, equities analysts clearly believe Solventum is more favorable than Penumbra.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solventum	1 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.46
Penumbra	0 Sell rating(s)	14 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.18

Solventum has a net margin of 17.33% compared to Penumbra's net margin of 11.76%. Solventum's return on equity of 23.51% beat Penumbra's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solventum	17.33%	23.51%	7.63%
Penumbra	11.76%	10.87%	8.45%

Solventum has higher revenue and earnings than Penumbra. Solventum is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solventum	$8.33B	1.55	$1.56B	$8.16	9.12
Penumbra	$1.40B	9.04	$177.69M	$4.34	74.30

Summary

Solventum beats Penumbra on 9 of the 16 factors compared between the two stocks.

Get Solventum News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SOLV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SOLV vs. The Competition

Export

Metric	Solventum	Medical Services Industry	Medical Sector	NYSE Exchange
Market Cap	$13.01B	$8.31B	$6.30B	$22.96B
Dividend Yield	N/A	2.92%	2.79%	4.07%
P/E Ratio	9.12	22.95	21.00	28.29
Price / Sales	1.55	15.56	554.55	24.51
Price / Cash	8.36	83.95	42.94	25.11
Price / Book	2.59	5.62	9.75	4.73
Net Income	$1.56B	$183.43M	$3.55B	$1.07B
7 Day Performance	3.93%	0.28%	-0.53%	-1.11%
1 Month Performance	7.84%	5.23%	1.20%	1.36%
1 Year Performance	4.90%	4.94%	41.22%	24.41%

Solventum Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SOLV Solventum	3.2315 of 5 stars	$74.43 -0.9%	$85.91 +15.4%	+0.9%	$13.01B	$8.33B	9.12	20,000
GEHC GE HealthCare Technologies	4.9477 of 5 stars	$61.70 -2.8%	$80.67 +30.7%	-16.2%	$28.87B	$20.63B	14.76	54,000	Insider Trade
PHG Koninklijke Philips	2.6858 of 5 stars	$26.75 -1.7%	N/A	+5.9%	$26.20B	$20.17B	22.92	65,340	Gap Down
ZBH Zimmer Biomet	4.5394 of 5 stars	$79.67 -3.2%	$102.80 +29.0%	-15.1%	$15.93B	$8.23B	20.69	17,000	Positive News
SNN Smith & Nephew SNATS	2.5601 of 5 stars	$29.12 -2.8%	$30.93 +6.2%	+5.6%	$12.79B	$6.16B	N/A	16,988	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:SOLV) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Solventum (SOLV) Competitors

SOLV vs. GEHC, PHG, ZBH, SNN, and PEN

How does Solventum compare to GE HealthCare Technologies?

Summary

How does Solventum compare to Koninklijke Philips?

Summary

How does Solventum compare to Zimmer Biomet?

Summary

How does Solventum compare to Smith & Nephew SNATS?

Summary

How does Solventum compare to Penumbra?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SOLV vs. The Competition

Solventum Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Solventum (SOLV) Competitors

SOLV vs. GEHC, PHG, ZBH, SNN, and PEN

How does Solventum compare to GE HealthCare Technologies?

Does the media refer more to SOLV or GEHC?

Do analysts prefer SOLV or GEHC?

Which has higher earnings & valuation, SOLV or GEHC?

Is SOLV or GEHC more profitable?

Do institutionals and insiders have more ownership in SOLV or GEHC?

Which has more volatility and risk, SOLV or GEHC?

Summary

How does Solventum compare to Koninklijke Philips?

Which has preferable earnings & valuation, PHG or SOLV?

Does the media favor PHG or SOLV?

Do insiders and institutionals believe in PHG or SOLV?

Do analysts recommend PHG or SOLV?

Which has more volatility & risk, PHG or SOLV?

Is PHG or SOLV more profitable?

Summary

How does Solventum compare to Zimmer Biomet?

Which has preferable earnings & valuation, ZBH or SOLV?

Does the media favor ZBH or SOLV?

Do insiders and institutionals believe in ZBH or SOLV?

Do analysts recommend ZBH or SOLV?

Which has more volatility & risk, ZBH or SOLV?

Is ZBH or SOLV more profitable?

Summary

How does Solventum compare to Smith & Nephew SNATS?

Does the media favor SNN or SOLV?

Do analysts recommend SNN or SOLV?

Is SNN or SOLV more profitable?

Which has more risk & volatility, SNN or SOLV?

Which has better earnings and valuation, SNN or SOLV?

Do institutionals and insiders believe in SNN or SOLV?

Summary

How does Solventum compare to Penumbra?

Does the media prefer SOLV or PEN?

Do institutionals & insiders have more ownership in SOLV or PEN?

Which has more volatility and risk, SOLV or PEN?

Do analysts recommend SOLV or PEN?

Is SOLV or PEN more profitable?

Which has higher valuation & earnings, SOLV or PEN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SOLV vs. The Competition

Solventum Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools